Inxight Drugs

U.S. Department of Health & Human Services Divider Arrow

National Institutes of Health Divider Arrow

NCATS

Return Home Inxight Drugs

Home
Browse Drugs
Search
- Structure Search
- Sequence Search
Downloads
About

Show Filters

Hide Filters

Development Status

Investigational

1

Possibly Marketed Outside US

1

US Approved Rx

1

All Match

Any Match

Exclude Selected

Exclude Selected

Primary Target

C-C chemokine receptor type 2

1

All Match

Any Match

Exclude Selected

Exclude Selected

Highest Phase

Approved

1

All Match

Any Match

Exclude Selected

Exclude Selected

Approval Year

2022

1

2023

1

Unknown

1

All Match

Any Match

Exclude Selected

Exclude Selected

Condition

Chronic hepatitis B

1

Crohn's disease

1

Nonalcoholic steatohepatitis

1

All Match

Any Match

Exclude Selected

Exclude Selected

Treatment Modality

Primary

1

All Match

Any Match

Exclude Selected

Exclude Selected

Originator

Bristol-Myers Squibb

1

Mironov, V.F. et al.

1

All Match

Any Match

Exclude Selected

Exclude Selected

Substance Class

Chemical

2

Protein

1

All Match

Any Match

Exclude Selected

Exclude Selected

Code System

CAS

3

ChEMBL

3

EU-Orphan Drug

3

FDA ORPHAN DRUG

3

FDA UNII

3

All Match

Any Match

Exclude Selected

Exclude Selected

Protein Type

MONOCLONAL ANTIBODY

1

All Match

Any Match

Exclude Selected

Exclude Selected

Substance Form

Principal Form

3

All Match

Any Match

Exclude Selected

Exclude Selected

Search results for "EU ORPHAN DRUG|Positive|Treatment of focal segmental glomerulosclerosis" in comments (approximate match)

Showing 1 - 3 of 3 results

First page disabled
Previous page disabled
1
Next page disabled
Next page disabled

SPARSENTAN

9242RO5URM

Export Data
Search for Structure

Status:

US Approved Rx (2023)

First approved in 2023

Class (Stereo):

CHEMICAL (ACHIRAL)

Targets:

Type-1 angiotensin II receptor

Endothelin receptor ET-A

Conditions:

Primary immunoglobulin A nephropathy

Sparsentan (RE-021; BMS-346567; PS433540; DARA-a) is a novel candidate in development by Retrophin for the treatment of focal segmental glomerulosclerosis (FSGS), a serious kidney disorder that often leads to end-stage renal disease (ESRD). Sparsent...

an is a single molecule with antagonism of the endothelin type A receptor (ETAR) and the angiotensin II type 1 receptor (AT1R). Sparsentan has high affinity for both the ETAR (Ki= 12.8 nM) and the AT1R (Ki=0.36 nM), and greater than 500-fold selectivity for these receptors over the endothelin type B and angiotensin II subtype 2 receptors. Endothelin-1 and angiotensin II are thought to contribute to the pathogenesis of IgAN via the ETAR and AT1R, respectively. The US Food and Drug Administration gave accelerated approval on February 17 2023 to sparsentan (Filspari), the first non-immunosuppressive therapy labeled for treating adults with primary immunoglobulin A (IgA) nephropathy.

PROPAGERMANIUM

1Q2P9TO9Q7

Export Data
Search for Structure

Status:

Possibly Marketed Outside US

First approved in 2022

Class (Stereo):

CHEMICAL (ACHIRAL)

Targets:

C-C chemokine receptor type 2

Conditions:

Chronic hepatitis B

Nonalcoholic steatohepatitis

Crohn's disease

Propagermanium, a newly introduced hydrophilic polymer of 3-oxygermanium propionic acid (3,3’-(1,3- dioxo-1,3-digermoxanediyl) bispropionic acid) has been reported to have antiinflammatory, antiviral and antineoplastic properties. In Japan propagerma...

nium is approved for the treatment of HBe positive chronic hepatitis B. A postmarketing survey, however, revealed the occurrence of moderate to severe liver damage after the treatment in about 4% of patients. In most countries propagermanium falls under the regulations of dietary supplements. An import alert on germanium products was imposed by the U.S. FDA in 1988, because of possible injury to health. In Germany governmental institutions warned consumers of possibly fatal kidney damage.

FRESOLIMUMAB

375142VBIA

Subunit 1 (447) Similarity Search Subunit 2 (447) Similarity Search Subunit 3 (215) Similarity Search Subunit 4 (215) Similarity Search

Export Data
Sequence Search

Subunit 1 (447) Similarity Search Subunit 2 (447) Similarity Search Subunit 3 (215) Similarity Search Subunit 4 (215) Similarity Search

Status:

Investigational

Class:

PROTEIN

HHS VULNERABILITY DISCLOSURE

For language access assistance, contact the NCATS Public Information Officer

National Center for Advancing Translational Sciences (NCATS),
6701 Democracy Boulevard, Bethesda MD 20892-4874 • 301-594-8966


			version 1.1